FDA Grants Rolling NDA for COMP360, Awards Priority Review Voucher, Accelerating Approval Timeline
CMPS has more than doubled off its 52-week low of $2.25.
Summary
COMPASS Pathways announced that the FDA has granted a rolling New Drug Application (NDA) submission and review for COMP360, its psilocybin therapy for treatment-resistant depression (TRD). Crucially, the company was also awarded a Commissioner's National Priority Review Voucher (CNPV), which has the potential to accelerate the FDA's review timeline to just 1-2 months. This significantly advances the regulatory path, with the final NDA submission still on track for Q4 2026 and the company aiming to be launch-ready by year-end. Additionally, COMPASS reported a strong cash position of $466 million at the end of Q1 2026, providing a cash runway well beyond launch and into 2028. This news represents a major positive catalyst, de-risking the commercialization timeline and strengthening the company's financial standing, making it highly actionable for traders.
At the time of this announcement, CMPS was trading at $9.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $900.3M. The 52-week trading range was $2.25 to $10.21. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.